Celerion achieves major milestone of successfully analyzing over 25,000 platelet aggregation samples.
Celerion’s unmatched experience in platelet aggregation benefits clients by producing higher quality data, reduced timelines and lower costs.
(Lincoln, NE; Jun 21, 2011) – Celerion, the premier provider of innovative early stage drug development solutions, announces it has achieved a major milestone of generating over 25,000 platelet aggregation sample results. These samples were collected from over 1000 participants dosed in more than 20 studies. Platelet function assays are inherently variable, so this level of experience is critical to produce reliable and accurate platelet aggregation results.
The FDA public health advisory, released in 2009, described the potential for reduced anti-blood clotting activity due to drug-drug interactions. This has led to an increased need for platelet aggregation studies to better evaluate the impact of drug-drug interactions on platelet function.
To meet this industry need and client demand, Celerion made significant investments to implement intensive staff training and added cutting edge technology. The fully trained staff, in combination with state-of-the-art analyzers has produced unparalleled precision. Equally important, by deploying this technology, Celerion has been able to increase cohort size on studies requiring platelet aggregation, from eight to 40 participants, creating efficiency in the conduct of these studies.
“Reaching this milestone is a testament to Celerion’s ability to respond to the evolving needs of early clinical research,” said Phil Bach, Vice President, Global Clinical Research. “Our experience has already benefited many clients in producing high quality data efficiently, to help them achieve their goal of getting products to market sooner.”
Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds, Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com.